Affymetrix signs first translational medicine agreement in China
Affymetrix and Zhejiang California Nanosystem Institute (ZCNI) at Zhejiang University have entered into a collaboration to develop clinical applications using GeneChip technology.
Affymetrix and Zhejiang California Nanosystem Institute (ZCNI) at Zhejiang University have entered into a collaboration to develop clinical applications using GeneChip technology.
It is Affymetrix' first translational medicine collaboration in China. ZCNI researchers will use Affymetrix GeneChip microarray technology for translational medicine research projects, beginning with cancer, newborn genetic diseases and infectious diseases.
The two organisations are also establishing a joint laboratory that will support clinical researchers at Zhejiang University and its six affiliated hospitals. The researchers will use Affymetrix GeneChip technology to analyse genomic information across large patient samples. The data will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage and treat clinically im-portant diseases, Affymetrix says.
Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and diagnostics community through its Translational Medicine Program to develop molecular signatures for improving patient care.